What is the recommended dose and concentration of Kenalog (triamcinolone acetonide) injections for a patient at risk of keloid formation after an incision?

Prophylactic Intralesional Triamcinolone After Incision for Keloid Prevention

For patients at risk of keloid formation after an incision, inject triamcinolone acetonide 10 mg/mL (diluted from the standard 40 mg/mL concentration) subdermally along both edges of the wound immediately after closure, using approximately 1 mL per ampule along each edge of the incision. 1

Evidence-Based Dosing Protocol

The most relevant study for your specific question involves injecting triamcinolone at the time of wound closure to prevent keloid recurrence:

• Concentration: Use 10 mg/mL triamcinolone acetonide (diluted from 40 mg/mL stock) 1
• Timing: Inject immediately after wound closure, before skin closure is complete 1
• Technique: Inject subdermally (just beneath the dermis in the upper subcutis) along the entire length of both the upper and lower edges of the skin incision 1, 2
• Volume: Use one 1 mL ampule (10 mg) along the upper edge and one 1 mL ampule (10 mg) along the lower edge of the incision 1
• Needle size: Use a 25-gauge needle for injection 1

Dilution Instructions

Yes, dilution is required for prophylactic use:

• The standard keloid treatment concentration is 40 mg/mL 3, 2
• For prophylactic injection at wound closure, dilute to 10 mg/mL using sterile normal saline 1
• This represents a 1:4 dilution (1 part triamcinolone 40 mg/mL + 3 parts sterile saline = 10 mg/mL final concentration)

Rationale for Lower Concentration

The lower concentration (10 mg/mL) for prophylactic use versus established keloid treatment (40 mg/mL) makes clinical sense because:

• You're treating normal tissue at risk rather than established pathologic scar tissue 1
• Lower concentrations minimize the risk of skin atrophy, pigmentary changes, and telangiectasias in fresh surgical wounds 3, 2
• The American Academy of Dermatology specifically recommends lower concentrations (5-10 mg/mL) for facial areas or sites at higher risk for atrophy 2

Expected Outcomes and Limitations

Important caveats about this approach:

• Even with established keloid treatment using higher concentrations (40 mg/mL), recurrence rates are 33% at 1 year and 50% at 5 years 4
• The prophylactic protocol at wound closure showed promising results in the trial design, but long-term efficacy data are still being collected 1
• For established keloids requiring treatment, the standard concentration is 40 mg/mL, repeated every 3-4 weeks until flattening occurs 3, 2

Critical Technical Points

Injection depth is crucial:

• Target the upper subcutis just beneath the dermis, NOT into the dermis itself or deeper subcutaneous fat 2
• Avoid injecting into tendon substance if near joints 2
• The goal is to create a depot effect along the wound edges where keloid formation typically begins 1

Contraindications to Avoid

Do not inject triamcinolone if:

• Active infection is present at the surgical site 3, 2
• Patient has known hypersensitivity to triamcinolone 3, 2
• Patient has active tuberculosis or systemic fungal infection 3, 2
• Exercise caution in patients with uncontrolled diabetes, heart failure, or severe hypertension 3, 2